NBIX Neurocrine Biosciences Forecast, Technical & Fundamental Analysis
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders... Show more
NBIX is expected to report earnings to fall 16.49% to $1.62 per share on July 30
Q2'26
Est.
$1.62
Q1'26
Beat
by $0.77
Q4'25
Beat
by $0.02
Q3'25
Beat
by $0.58
Q2'25
Beat
by $0.69
The last earnings report on May 05 showed earnings per share of $1.94, beating the estimate of $1.17. With 195.70K shares outstanding, the current market capitalization sits at 17.67B.
A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with AKBA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then AKBA could also see price increases.
NBIX in +1.78% Uptrend, growing for three consecutive days on July 24, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NBIX advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where NBIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 280 cases where NBIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for NBIX moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NBIX turned negative on July 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NBIX broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.187) is normal, around the industry mean (46.269). P/E Ratio (27.042) is within average values for comparable stocks, (100.083). NBIX's Projected Growth (PEG Ratio) (0.496) is slightly lower than the industry average of (1.733). NBIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (5.821) is also within normal values, averaging (116.105).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
